ABSTRACT:
Fesoterodine, a relatively new antimuscarinic medication used to treat overactive bladder, has undergone extensive testing in the elderly and has been linked to a notable improvement in both quality of life and disease-related outcomes. In this older patient population, fesoterodine also seems to be well tolerated. For many elderly persons, overactive bladder is a prevalent and problematic condition. In late 2008, the US Food and Drug use approved fesoterodine, a nonselective muscarinic-receptor antagonist, for once-daily oral use in the treatment of OAB to alleviate the symptoms of urgency, frequency, and incontinence. The prevalence of overactive bladder (OAB), a chronic illness that affects both men and women, rises with age. The mainstay of OAB treatment is antimuscarinics. The evidence for fesoterodine in older adults is covered in this review. There are numerous approaches for the examination of Fesoterodine HCI, according to the literature, so we compiled them all into a single review. High Performance Liquid Chromatography (HPLC), High Performance Thin Layer Chromatography (HPTLC), RP-HPLC, and the Stability Indicating assay method were used to monitor fesoterodine HCL for development and validation. The main emphasis is on chromatographic techniques, especially High-Performance Liquid Chromatography (HPLC), which is still the most popular method because of its precision, accuracy, and robustness. Critical validation parameters, such as linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ), are examined in compliance with the guidelines established by the International Council for Harmonization (ICH) and other regulatory authorities. A number of important factors involved in method development, such as column type, detection wavelength, and mobile phase compositions, are thoroughly discussed.